nVerses Capital’s Biohaven BHVN Stock Holding History

nVerses Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,000	Closed	-$50K	–	111
2024 Q3	$50K	Buy	+1,000	New	+$38.9K	0.02%	635

Other funds holding BHVN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

nVerses Capital's BHVN Position: Q4 2024 in Review

nVerses Capital sold out of Biohaven (BHVN) in Q4 2024, closing a stake of 1,000 shares — an estimated $50K sold.

nVerses Capital first reported a position in BHVN in Q3 2024 and held it in 1 quarter. The position peaked at $50K in Q3 2024. 256 funds tracked by Wall St. Rank hold BHVN as of Q4 2024.

nVerses Capital reported no remaining Biohaven position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 1,000 Biohaven shares in Q4 2024, an estimated $50K.
nVerses Capital first reported a position in Biohaven in Q3 2024 and held it in 1 quarter.
nVerses Capital's Biohaven position peaked at $50K in Q3 2024.
256 funds tracked by Wall St. Rank held Biohaven as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.